Industry Briefs: Apr. 2, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Albany Molecular Research has agreed to license to Bessor Pharma its tubulin-inhibitor program for treating cancer.
A federal district court has ruled in favor of AstraZeneca on its formulation patent for Seroquel (quetiapine fumarate) extended-release tablets.
BioStorage Technologies has expanded its services in the academic research sector throughout the northeast United States.
Eisai and Minophagen Pharmaceutical have concluded a license agreement concerning the development and commercialization of the cutaneous T-cell lymphoma treatment bexarotene.
Gerresheimer has acquired Neutral Glass.
GlaxoSmithKline has agreed to purchase 10 million shares to increase its ownership in Theravance.
Illumina’s board of directors has unanimously rejected Roche’s revised offer to acquire the company for $51 per share in cash.
Pharmaceutical Research and Manufacturers of America has issued a statement to support the National Governor’s Association’s Prescription Drug Abuse Reduction Policy Academy.
Sigma Aldrich has acquired Research Organics.
People News
Laureate Biopharma has named Lisa Cozza as vice-president of business development.
Merck has appointed Michael J. Holston as chief ethics and compliance officer, effective June 25, 2012. He will succeed Richard S. Bowles, who plans to retire from the company.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
